TA Associates, a global growth private equity firm, completed a majority growth investment in Elos Medtech, a full-service contract development and manufacturing organization in the global medical device market.
Founded in 1923, Elos Medtech is headquartered in Gothenburg, Sweden with operations in Sweden, Denmark, China and the U.S. Elos Medtech serves the dental, orthopaedic and life science markets.
“I am very pleased to welcome TA as the majority shareholder of Elos Medtech,” said Jan Wahlström, CEO of Elos Medtech. “Having completed more than 70 investments in healthcare businesses, including many in the medical device field, TA has the deep experience, network and global resources that we believe will prove highly beneficial at this stage of our growth. I thank all our shareholders as well as our skilled and motivated employees for their support of Elos Medtech and look forward to a close partnership with TA as we continue to further build a strong global group.”
On June 11, 2021, TA (through EM Intressenter) announced a public offer to the shareholders of Elos Medtech to tender all their shares in Elos Medtech to EM Intressenter for SEK 215 per share. On July 7, 2021, TA announced that the Offer would be completed and that the initial acceptance period, which ended on July 5, 2021, would be extended and open until July 14, 2021. The total amount of shares tendered in the Offer at the end of the extended acceptance period on July 14, 2021 amount in aggregate to approximately 79.5% of the share capital and 65.0% of the voting rights in Elos Medtech.
Source: TA Associates